Table 2.
Clinical Characteristics (n=1071)
| Variables | |
|---|---|
| Age, y | 64.8±10.2 |
| Male, n (%) | 713 (66.6%) |
| Current smoking, n (%) | 345 (32.2%) |
| Diabetes mellitus, n (%) | 364 (34.0%) |
| Hypertension, n (%) | 698 (65.2%) |
| Prior MI or stroke, n (%) | 228 (21.3%) |
| Acute MI, n (%) | 127 (11.9%) |
| Blood pressure, mm Hg | |
| Systolic | 134±19 |
| Diastolic | 77±11 |
| NYHA Grade III–IV, n (%) | 57 (5.3%) |
| Drugs | |
| ACEI/ARB | 524 (48.9%) |
| Statins | 922 (86.1%) |
| PCI, n (%) | 636 (59.4%) |
| Volume of CM, mL | 100 (60–150) |
| Baseline eGFR, mL/min per 1.73 m2 | 96.6 (80.5–114.4) |
| ≥90, n (%) | 644 (60.1%) |
| 60 to 89, n (%) | 358 (33.4%) |
| 30 to 59, n (%) | 64 (6.0%) |
| <30, n (%) | 5 (0.5%) |
| Mehran risk score | 4.0 (2.0–6.0) |
| ≤5, n (%) | 747 (69.7%) |
| 6 to 10, n (%) | 264 (24.7%) |
| ≥11, n (%) | 60 (5.6%) |
| sCr, mg/dL | |
| Baseline | 0.79 (0.67–0.94) |
| 24 to 48 hours post CM exposure | 0.82 (0.68–0.98)a |
| sCyC, mg/dL | |
| Baseline | 0.96 (0.82–1.17) |
| 24 to 48 hours post CM exposure | 0.97 (0.83–1.16) |
Continuous values are expressed as mean±SD or median (with 25th and 75th percentiles); categorical values are expressed as total number and proportion of the global population (in parentheses). ACEI indicates angiotensin‐converting enzyme inhibitors; ARB, angiotensin II receptor blockers; CM, contrast media; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; sCr, serum creatinine; sCyC, serum cystatin C.
a
P<0.001, compared with sCr at baseline.